Jon Ward

Among the Veterans' Health Administration (VHA), Predicting Risk of cardiovascular disease EVENTs (PREVENT) equation improves calibration and discrimination and can accurately predict 10-year ASCVD risk among Veterans ahajrnls.org/4oCQn9f

It would be interesting to see what the same analysis would result in different subgroups, such as renal patients and/or hypertensive patients. SGLT2s Best ARNIs in Frail, Older Adults With HFpEF medscape.com/viewarticle/sg…

$NTLA News: Intellia announces positive longer-term data from the ongoing Phase 1 trial in #ATTRamyloidosis with polyneuropathy and the company’s latest publication in @NEJM. Read the press release: ir.intelliatx.com/news-releases/…

Cardio Town Hall: Amyloidosis is June 12, get prepared with NEW CardioBites+: Amyloidosis to learn the different mechanisms of disease and why understanding these differences may impact management decisions for these patients. 13-minute watch >> youtu.be/Fzq7DPIlg_A

The Multi-Ethnic Study - MESA - 🤔"Group 1 LDL-C, mg/dL (SD) : 82.8 (14.6) Lp(a), mg/dL (IQR): 11.1 (5.1–22.2)" 🤔"Group 2 LDL-C, mg/dL (SD) : 131.5 (23.1) Lp(a), mg/dL (IQR): 14.3 (7.4–25.6)" 👉"Group 3: LDL-C≤100, Lp(a) ≥ 50" 👉"Group 4: LDL-C > 100, Lp(a) ≥ 50"

Knowledge is power, especially for your heart!🫀 Lipoprotein(a) [Lp(a)] is a genetic risk factor for heart disease & stroke. Identifying high Lp(a) levels early can help individuals take proactive steps to protect their #hearthealth. 📃Learn more: learnyourlipids.com/lipid-disorder…

Just published: 🫀Coronary Artery Calcium Scoring in the Context of Widespread Lipoprotein(a) Testing: Clinical Considerations and Implications for Lipid-Lowering Therapies🔬 🚨 New insights from Palanisamy, Burka & Blaha (2025) show Lp(a) & CAC aren’t just independent risk factors—they amplify each other! CAC exposes hidden atherosclerosis, while Lp(a) fuels thrombotic risk, making them essential first-line tests for primary prevention. With Lp(a)-lowering therapies emerging, their role in high-CAC patients needs urgent study. Is CAC-guided Lp(a) therapy the future? #CVprev @foundationofnla @Heart_SCCT @MichaelJBlaha @rblument1 @PalanisamySri @SBurkaMD 📖 Read more: doi.org/10.1007/s11886…

This picture is so profound. With 10 years of working in the ICU, there were several times when it felt like just because we can doesn’t mean we should. As one nurse put it “you’re slapping back the hand of Jesus” - the crocs are a nice added touch to the picture BTW

In our new study in EJPC, optimal CVD risk factor control was a/w lower risk across Lp(a) levels, though residual risk remains. These results show the importance of aggressive risk factor mgmt in patients with elevated Lp(a). @AlexRazavi @Lpa_Doc academic.oup.com/eurjpc/advance…

#AHA24 ICYMI: #JACC AE Dr. @MarcBonaca and Dr. @Lpa_Doc discuss new insights from the MESA cohort about OxPL-apoB and risk for calcific aortic valve disease 👇 📄: bit.ly/3YRMeDf

@drstaceyrosen @AHAScience @DrLaxmiMehta @DrJMieres @gina_lundberg Congrats Dr. Volgman! @avolgman well deserved!!!

Congratulations to my friend and colleague , Annabelle Volgman,MD! A n extraordinary scientist , clinician educator and mentor!!! ⁦@AHAScience⁩ ⁦@DrLaxmiMehta⁩ ⁦@DrJMieres⁩ ⁦@gina_lundberg⁩

#AHA24: How does OxPL-apoB affect the risk of calcific aortic valve disease? Using data from MESA, Drs. @hsbhatia, @Lpa_Doc & team show that ⬆️ OxPL-apoB is associated with increased incidence and progression of valve disease bit.ly/3YRMeDf #JACC

Lipoprotein, Lp(a) and LDL-cholesterol, LDL-C, are independent and additive for cardiovascular risk. Reduction in LDL-C cannot fully offset Lp(a)-mediated risk suggesting a need for targeted therapy for both. @PeterWilleit @hsbhatia @Lpa_doc ahajournals.org/doi/abs/10.116…

"This is why you come to Oregon." #GoDucks

@Abraham_Jacob @HowardHWhite @Jumpman23 @Nike @Ludacris @christuckerreal Wow! 👏 👏 👏 great work and video

“H” White’s belief in the importance of giving back is an inspiration. I am honored to have played a role in his care and in the center which now bears his name. Thank you ⁦@HowardHWhite⁩ ⁦@Jumpman23⁩ ⁦ @Nike⁩ ⁦@Ludacris⁩ ⁦@christuckerreal⁩

An estimated 1.19 million deaths per year could be prevented with optimal implementation of GDMT for heart failure with reduced ejection fraction globally. @GCFMD ja.ma/3NaKb7C

Our new expert consensus document justifies why Indian and other South Asian patients at extreme ASCVD risk need to have LDL-C targets of 30 mg/dl and even lower to 10-15 mg/dl in those still suffering recurrent events.

@AAgarwalaMD @HeartPlano @jaideeppatelmd @PSatishMD @SuvasiniL @khurramn1 @JavedButler1 @ShahzebKhanMD @NeilKeshvani @JSpitz_MD @RomitB_MD @GarimaVSharmaMD @AmroAlsaid Do you have the doi link? I’d love to read it! Congrats 🍾

No better way to celebrate the acceptance of our first manuscript (of many) from the #DILWALE South Asian CV health registry and an awesome research team than with samosas, mango lassi & cake! @HeartPlano! @jaideeppatelmd

Higher Lp(a) levels were associated with increased progression of coronary plaque burden and increased presence of low-density noncalcified plaque and pericoronary adipose tissue inflammation. ja.ma/3BoACQ5

@quin_denfeld @RiegelBarbara @csleern @NINR @OHSUNursing @ShirinHiatt Is Chris visiting or back?! Highly impactful researchers and authors in Oregon 👍

Just wrapped up a FABULOUS few days with two esteemed leaders in our field @RiegelBarbara & @csleern!! I’m so fortunate to have their expertise on our two @NINR - funded projects! #HeartFailure #Symptoms #Frailty #WomensHealth @OHSUNursing @ShirinHiatt